An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Hepatology. 2011 Oct;54(4):1433-44. doi: 10.1002/hep.24641. Epub 2011 Sep 26.
No abstract available

Publication types

  • Comparative Study
  • Practice Guideline

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Drug Resistance, Viral
  • Female
  • Genotype
  • Hepacivirus / drug effects
  • Hepacivirus / genetics*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics*
  • Hepatitis C, Chronic / physiopathology
  • Humans
  • Male
  • Oligopeptides / therapeutic use
  • Prognosis
  • Proline / analogs & derivatives
  • Proline / therapeutic use
  • Protease Inhibitors / therapeutic use*
  • Randomized Controlled Trials as Topic / standards
  • Recurrence
  • Risk Assessment
  • Societies, Medical
  • Treatment Outcome
  • United States

Substances

  • Antiviral Agents
  • Oligopeptides
  • Protease Inhibitors
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline